Advertisement
Canada markets closed
  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     
  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     
  • DOW

    37,815.92
    -570.17 (-1.49%)
     
  • CAD/USD

    0.7259
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    81.10
    -0.83 (-1.01%)
     
  • Bitcoin CAD

    82,366.60
    -5,567.95 (-6.33%)
     
  • CMC Crypto 200

    1,280.77
    -58.29 (-4.35%)
     
  • GOLD FUTURES

    2,298.10
    -4.80 (-0.21%)
     
  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     
  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     
  • NASDAQ futures

    17,519.25
    -52.00 (-0.30%)
     
  • VOLATILITY

    15.65
    +0.98 (+6.68%)
     
  • FTSE

    8,144.13
    -2.90 (-0.04%)
     
  • NIKKEI 225

    38,190.93
    -214.73 (-0.56%)
     
  • CAD/EUR

    0.6808
    +0.0006 (+0.09%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
Cellectis Inc.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, April 04, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

03/31/2024

71,953,535

77,889,229

For further information on Cellectis, please contact:

Media contact:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com

Investor Relations contacts:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577


Attachment